Overview

Phase 1b Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable Hepatocellular Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

The study will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in first line setting in patients with unresectable hepatocellular carcinoma.The study drug which is tested is the NP137 in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.

Phase:

Phase 1

Details

Lead Sponsor:

University Hospital, Grenoble

Collaborator:

NETRIS Pharma

Treatments:

Atezolizumab
Bevacizumab